Close Menu

NEW YORK – Guardant Health reported after the close of the market on Thursday that its third quarter 2020 revenues were up 23 percent year over year.

The liquid biopsy firm reported total revenues of $74.6 million for the quarter ended Sept. 30 compared to $60.8 million in the same period of 2019, beating the consensus Wall Street estimate of $65.9 million.

Guardant's oncology testing revenues in Q3 2020 rose 16 percent year over year to $60.4 million from $52.1 million. Development services revenues jumped up 65 percent to $14.2 million from $8.7 million in Q3 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.